Back to Journals » Clinical Ophthalmology » Volume 7

Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma

Authors Inoue K, Tanaka A, Tomita G, Fujimoto T

Received 6 April 2013

Accepted for publication 27 May 2013

Published 9 July 2013 Volume 2013:7 Pages 1411—1416


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Kenji Inoue,1 Ayumi Tanaka,1 Goji Tomita2

1Inouye Eye Hospital, 22nd Department of Ophthalmology, Toho University School of Medicine, Tokyo, Japan

Purpose: To evaluate the effects of tafluprost treatment for 3 years on intraocular pressure (IOP) and visual field performance.
Methods: The IOP of 55 patients with normal-tension glaucoma was monitored every 1–3 months for 3 years. The Humphrey visual field test was performed every 6 months after treatment and results compared with before-treatment results. Visual field performance was also evaluated by trend and event analysis.
Results: After 3 years’ tafluprost single-use vials treatment, the IOP (12.8 ± 2.8 mmHg [mean ± standard deviation]) was significantly lower than before treatment (15.7 ± 2.2 mmHg; P < 0.0001). When comparing before-treatment Humphrey visual field test findings with those after 3 years of treatment, no change was found in the mean deviation and pattern standard deviation. Visual field performance had worsened in four patients and three patients according to trend analysis and event analysis, respectively. Adverse reactions appeared in ten cases and one patient (1.8%) discontinued treatment due to an adverse reaction.
Conclusion: Tafluprost single-use vials treatment was effective in reducing IOP over the 3 years of this study, but visual field performance worsened by 10.3%–13.8% in patients with normal-tension glaucoma. Safety was satisfactory.

Keywords: intraocular pressure, visual field, trend analysis, event analysis

A Letter to the Editor has been received and published for this article.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma

Inoue K, Shiokawa M, Fujimoto T, Tomita G

Clinical Ophthalmology 2014, 8:1179-1183

Published Date: 19 June 2014

Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma

Inoue K, Iwasa M, Wakakura M, Tomita G

Clinical Ophthalmology 2012, 6:1315-1319

Published Date: 15 August 2012

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy

Inoue K, Fujimoto T, Higa R, Moriyama R, Kohmoto H, Nagumo H, Wakakura M, Tomita G

Clinical Ophthalmology 2012, 6:771-775

Published Date: 21 May 2012

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension

Inoue K, Shiokawa M, Sugahara M, Higa R, Wakakura M, Tomita G

Clinical Ophthalmology 2012, 6:111-116

Published Date: 12 January 2012

Effect of five years of treatment with nipradilol eye drops in patients with normal tension glaucoma

Inoue K, Noguchi K, Wakakura M, Tomita G

Clinical Ophthalmology 2011, 5:1211-1216

Published Date: 26 August 2011

Effects of unoprostone on diurnal variation of intraocular pressure in healthy volunteers

Inoue K, Noguchi K, Wakakura M, Tomita G

Clinical Ophthalmology 2011, 5:1003-1005

Published Date: 15 July 2011

Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months

Kenji Inoue, Mieko Masumoto, Masato Wakakura, et al

Clinical Ophthalmology 2011, 5:393-396

Published Date: 22 March 2011

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010